➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Moodys
Merck
Dow
Baxter

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

Patent Applications for dicyclomine hydrochloride

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

US Patent Applications for dicyclomine hydrochloride

US Patent Application Patent No. Title Patent Filing Date Patent Application Status Status Updated
  Start Trial   Start Trial FATTY ACID-PHARMACEUTICAL AGENT CONJUGATES 2000-12-05 Patented Case 2003-05-21
  Start Trial   Start Trial Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction 2001-03-02 Abandoned -- Failure to Respond to an Office Action 2003-05-19
  Start Trial   Start Trial TRANSDERMAL ADMINISTRATION OF OXYBUTYNIN USING HYDROXIDE-RELEASING AGENTS AS PERMEATION ENHANCERS 2000-12-14 Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362 2011-06-13
  Start Trial   Start Trial Compositions and methods to effect the release profile in the transdermal administration of active agents 2001-01-19 Expressly Abandoned -- During Examination 2002-03-20
  Start Trial   Start Trial DHA-PHARMACEUTICAL AGENT CONJUGATES T0 IMPROVE TISSUE SELECTIVITY 2001-05-01 Patented Case 2003-07-17
  Start Trial   Start Trial DRUG DELIVERY DEVICE 2001-04-20 Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362 2012-08-06
  Start Trial   Start Trial Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects 2001-03-28 Abandoned -- Failure to Respond to an Office Action 2003-10-29
>US Patent Application >Patent No. >Title >Patent Filing Date >Patent Application Status >Status Updated

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.